BMS-354825 in Patients With Chronic Accelerated, or Blast Phase Chronic Myelogenous Leukemia or Philadelphia Positive Acute Lymphoblastic Leukemia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00103701|
Recruitment Status : Completed
First Posted : February 15, 2005
Last Update Posted : April 14, 2011
|Condition or disease||Intervention/treatment||Phase|
|Leukemia, Myeloid, Chronic-phase Leukemia, Lymphoblastic, Acute, Philadelphia-positive||Drug: Dasatinib||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase I Study of BMS-354825 in Patients With Chronic Accelerated, or Blast Phase Chronic Myelogenous Leukemia or Philadelphia Positive Acute Lymphoblastic Leukemia|
|Study Start Date :||November 2003|
|Actual Primary Completion Date :||March 2006|
|Actual Study Completion Date :||March 2006|
Tablets, Oral, 15- 240 mg, Once or twice daily, 0-3 years depending on response.
Other Name: Sprycel
- Establishment of MTD and recommended Phase II dose.
- 1) Hematologic Response 2) Cytogenetic Response.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00103701
|United States, California|
|Los Angeles, California, United States|
|United States, Texas|
|Houston, Texas, United States|
|Study Director:||Bristol-Myers Squibb||Bristol-Myers Squibb|